INOVIO PHARMACEUTICALS INC's ticker is INO and the CUSIP is 45773H201. A total of 203 filers reported holding INOVIO PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 1.42 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,041 | -12.9% | 30,953 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $13,821 | -45.5% | 30,953 | 0.0% | 0.00% | -33.3% |
| Q1 2023 | $25,381 | -47.4% | 30,953 | 0.0% | 0.00% | -57.1% |
| Q4 2022 | $48,287 | -8.9% | 30,953 | 0.0% | 0.01% | -22.2% |
| Q3 2022 | $53,000 | -1.9% | 30,953 | 0.0% | 0.01% | +12.5% |
| Q2 2022 | $54,000 | -51.4% | 30,953 | 0.0% | 0.01% | -46.7% |
| Q1 2022 | $111,000 | -27.0% | 30,953 | +1.3% | 0.02% | -25.0% |
| Q4 2021 | $152,000 | -30.9% | 30,548 | -1.0% | 0.02% | -33.3% |
| Q3 2021 | $220,000 | -23.1% | 30,842 | 0.0% | 0.03% | -23.1% |
| Q2 2021 | $286,000 | +1.4% | 30,842 | +1.4% | 0.04% | -7.1% |
| Q1 2021 | $282,000 | +9.7% | 30,402 | +4.6% | 0.04% | -4.5% |
| Q4 2020 | $257,000 | – | 29,076 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Green Alpha Advisors, LLC | 570,049 | $221,749 | 0.17% |
| GMT CAPITAL CORP | 1,513,500 | $588,752 | 0.02% |
| Cedar Brook Financial Partners, LLC | 130,522 | $50,773 | 0.01% |
| Arlington Capital Management, Inc. | 27,735 | $10,789 | 0.01% |
| GSA CAPITAL PARTNERS LLP | 296,948 | $116 | 0.01% |
| Keystone Financial Group | 109,897 | $42,751 | 0.01% |
| Hennion & Walsh Asset Management, Inc. | 163,562 | $63,626 | 0.00% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 1,149,974 | $447,340 | 0.00% |
| Freedom Investment Management, Inc. | 62,298 | $24,234 | 0.00% |
| Renaissance Technologies | 4,889,500 | $1,902 | 0.00% |